Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domestic ticagrelor (Taiyi) versus Brilinta in ACS patients undergoing PCI
ChiCTR1900023826Phase 4Not yet recruiting
- Sponsor
- Tianjin Union Medical Center
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor in acute coronary syndrome (ACS) and coronary arteriosclerosis (2 arms), sponsored by Tianjin Union Medical Center. Primary endpoint: Platelet aggregation rate. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900023826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023826.